AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Erik van den Berg, Chief Executive Officer, and Lars Boesgaard, Chief Financial
AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that members of its senior management team are scheduled to participate in the following
DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous28.02.2022 / 01:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Dis.
05.01.2022 - Press Release Stockholm, Sweden, January 5, 2022 Immunicum Transfers Patent Rights for Modified Adenovirus to Elicera Therapeutics Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors .